PAX3 and rhabdomyosarcoma: Genetic and pharmacologic inhibition of KDM4B (JMJD2B) substantially delayed tumor growth in preclinical subcutaneous xenograft models of PAX3-FOXO1-driven alveolar rhabdomyosarcoma [175].